No Data
No Data
CCORF Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $6
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March
Promising Developments in Tenaya Therapeutics' TN-201 Program Justify Buy Rating
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Stock Price Dropped 13% Last Week; Individual Investors Would Not Be Happy
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Unlock the Full List